Overview:
A synthetic analog of insulin-like growth factor-1 (IGF-1) featuring an arginine substitution at position 3 and a 13-amino acid N-terminal extension. The structural modification significantly extends its half-life compared to native IGF-1 by reducing binding affinity to IGF-binding proteins (IGFBPs). It has been the subject of published preclinical research examining its role in anabolic signaling and cellular growth regulation.
Research areas include:
- IGF-1 receptor (IGF-1R) binding and PI3K/Akt/mTOR pathway activation
- IGFBP binding resistance and extended systemic activity
- Skeletal muscle satellite cell proliferation and differentiation
- Nitrogen retention and protein synthesis in muscle tissue models
- Adipose tissue lipolysis and glucose transporter (GLUT4) regulation
- Neurotrophin-like effects and CNS cell survival models
Compound Specifications
| Property | Value |
|---|---|
| CAS# | 946870-92-4 |
| Formula | C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉ |
| Molecular Weight | 9117.6 g/mol |
| Class | Long-acting IGF-1 analog |
| Appearance | White to off-white lyophilized powder |
| Purity | ≥99% HPLC |
| Storage | -20°C, protect from light |
| Reconstitution | Bacteriostatic water (0.6% benzyl alcohol) |
